News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
23,357 Results
Type
Article (4723)
Company Profile (3)
Press Release (18631)
Section
Business (8605)
Career Advice (115)
Deals (1398)
Drug Delivery (14)
Drug Development (4125)
Employer Resources (20)
FDA (725)
Job Trends (1051)
News (14343)
Policy (1887)
Tag
Academia (110)
Alliances (1997)
Alzheimer's disease (30)
Antibody-drug conjugate (ADC) (17)
Approvals (718)
Bankruptcy (8)
Best Places to Work (666)
Breast cancer (15)
Cancer (53)
Cardiovascular disease (9)
Career advice (90)
Cell therapy (10)
Clinical research (2731)
Collaboration (20)
COVID-19 (920)
C-suite (12)
Data (36)
Diagnostics (176)
Diversity, equity & inclusion (7)
Drug pricing (18)
Duchenne muscular dystrophy (11)
Earnings (1906)
Employer branding (6)
Employer resources (19)
Events (1875)
Executive appointments (36)
FDA (742)
Funding (16)
Gene editing (7)
Gene therapy (27)
GLP-1 (73)
Government (494)
Healthcare (633)
Infectious disease (937)
Inflammatory bowel disease (10)
Interviews (12)
IPO (353)
IRA (13)
Job creations (413)
Job search strategy (85)
Layoffs (45)
Legal (543)
Lung cancer (9)
Lymphoma (8)
Manufacturing (6)
Medical device (83)
Medtech (83)
Mergers & acquisitions (1049)
Metabolic disorders (25)
Neuroscience (36)
NextGen Class of 2024 (226)
Non-profit (106)
Northern California (38)
Obesity (13)
Opinion (43)
Patents (12)
People (4033)
Phase I (813)
Phase II (1093)
Phase III (1298)
Pipeline (22)
Podcasts (18)
Policy (18)
Postmarket research (202)
Preclinical (236)
Prostate cancer (7)
Rare diseases (23)
Real estate (244)
Recruiting (7)
Regulatory (989)
Research institute (129)
Resumes & cover letters (21)
RSV (17)
Sickle cell disease (10)
Southern California (22)
Startups (287)
The Weekly (18)
United States (321)
Vaccines (331)
Weight loss (21)
Date
Last 7 days (5)
Last 30 days (45)
Last 365 days (1078)
2025 (3)
2024 (1090)
2023 (1161)
2022 (2821)
2021 (2692)
2020 (2119)
2019 (1257)
2018 (1059)
2017 (1257)
2016 (1142)
2015 (1414)
2014 (862)
2013 (730)
2012 (921)
2011 (1019)
2010 (752)
Location
Africa (85)
Asia (1461)
Australia (197)
California (68)
Canada (23)
China (8)
Connecticut (16)
Europe (3989)
Florida (11)
Japan (7)
Maryland (17)
Massachusetts (67)
New Jersey (14)
New York (69)
North Carolina (9)
Northern California (38)
Pennsylvania (20)
South America (80)
Southern California (22)
Washington State (8)
23,357 Results for "pfizer".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Phase III
Pfizer’s Ibrance Improves Survival in New Breast Cancer Indication
Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence supporting the CDK4/6 inhibitor class’ use in patients with a specific type of breast cancer.
December 12, 2024
·
1 min read
·
Annalee Armstrong
Gene therapy
Sangamo’s Stock Plummets as Pfizer Axes Hemophilia Gene Therapy Pact
Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments from Pfizer.
January 2, 2025
·
2 min read
·
Nick Paul Taylor
Drug development
5 Sickle Cell Therapies to Watch Following Pfizer’s Oxbryta Exit
In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy,
BioSpace
looks at five investigational drugs currently making their way through the pipeline.
October 21, 2024
·
4 min read
·
Kate Goodwin
Executive Appointments
Pfizer Shakes Up C-Suite, Elevating Cancer Chief Boshoff to CSO
Chris Boshoff will take over as Pfizer’s next chief scientific officer as of January 1, replacing Mikael Dolsten who led the pharma through the COVID-19 pandemic. The move comes weeks after Pfizer faced pressure from activist investor Starboard Value.
November 20, 2024
·
2 min read
·
Annalee Armstrong
Drug Development
BridgeBio Wins FDA Approval for ATTR-CM Drug, Launching Competition With Pfizer
BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a significant boost in the market against Pfizer’s tafamidis and potentially Alnylam’s Amvuttra.
November 23, 2024
·
8 min read
·
Heather McKenzie
Government
Lilly, Pfizer Execs Sing Optimistic Tune on Incoming Admin After Trump Dinner
A week after dining with Trump and his team at Mar-a-Lago, leaders at Pfizer and Eli Lilly have publicly stated that they intend to collaborate with the incoming administration on key issues affecting the pharma industry.
December 12, 2024
·
2 min read
·
Tristan Manalac
Podcast
Pfizer’s Q3 Earnings Win, Deals Galore, Countdown to Election, More
Pfizer, Sanofi and others report Q3 beats; AbbVie, Roche and Novartis strike big deals; the 2024 presidential election looms; and
BioSpace
takes a look back at 10 years of NextGen, our annual pick of young biotechs to watch.
October 30, 2024
·
1 min read
·
Heather McKenzie
Sickle Cell Disease
Pfizer’s Oxbryta Withdrawal Leaves Sickle Cell Community Scrambling, Investors Reeling
Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in sales by the end of the decade, has left patients and healthcare providers with few options, while investors question the pharma giant’s dealmaking prowess.
September 27, 2024
·
7 min read
·
Annalee Armstrong
RSV
Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age. Tuesday’s label expansion covers younger adults who are deemed at higher risk of RSV-related lower respiratory tract disease.
October 23, 2024
·
2 min read
·
Tristan Manalac
Vaccines
CDC Panel Recommends Merck and Pfizer Pneumococcal Vaccines for Adults Aged 50–64
The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.
October 24, 2024
·
2 min read
·
Tristan Manalac
1 of 2,336
Next
